Human Albumin Baxalta

Human Albumin Baxalta is a sterile solution for injection containing human serum albumin as the active ingredient. It is supplied in an unspecified strength and is marketed in the European Union as a prescription‑only plasma protein product. The formulation is intended for intravenous administration to increase plasma oncotic pressure and support intravascular volume in clinical situations requiring volume expansion, and may be used under physician supervision in acute care settings.

Human Albumin Baxalta is employed in clinical practice primarily as a plasma volume expander and to correct low serum albumin levels.

- Treatment of hypovolemia secondary to burns, trauma, or surgery. - Management of hypoalbuminemia in patients with liver disease, nephrotic syndrome, or malnutrition. - Support of circulatory volume in septic shock or severe sepsis when fluid resuscitation is needed. - Adjunct therapy during cardiopulmonary bypass or extracorporeal membrane oxygenation (ECMO). - Replacement therapy in patients with massive plasma loss during plasmapheresis.

Adverse reactions to Human Albumin Baxalta can vary in frequency and severity.

Common: - Fever or chills - Transient hypotension or hypertension - Rash or urticaria - Headache - Nausea or vomiting - Mild edema at infusion site

Serious: - Anaphylactic or severe allergic reactions - Volume overload leading to pulmonary edema - Hemolysis - Thromboembolic events such as deep vein thrombosis - Acute kidney injury - Severe hypotension requiring intervention

Before administering Human Albumin Baxalta, clinicians should evaluate patient-specific factors and monitor for potential complications.

- Assess volume status and cardiac function prior to infusion. - Monitor vital signs, fluid balance, and serum electrolytes during and after administration. - Use caution in patients with heart failure, renal insufficiency, or pulmonary disease. - Avoid rapid infusion rates to reduce the risk of hypotension or circulatory stress. - Screen for known hypersensitivity to human albumin or other plasma-derived products. - Consider the theoretical risk of infectious agent transmission despite donor screening.

Human Albumin Baxalta may interact with other medications or therapies that affect fluid balance or immune responses.

Avoid: - Concurrent use of additional volume expanders that could precipitate fluid overload. - Simultaneous administration of agents known to increase the risk of anaphylaxis, such as certain antibiotics.

Use with caution: - Diuretics, because combined effects may alter intravascular volume. - Anticoagulants, as changes in plasma volume can influence coagulation parameters. - Vasodilators or other antihypertensive drugs, which may exacerbate blood pressure fluctuations during infusion.